ABSTRACT

Introduction: Total lung-cancer–management costs are increasing dramatically. The widespread use of immune-checkpoint inhibitors (ICIs) explains this rise in large part and financially impacts healthcare systems. Economic assessment has been adapted to this new challenge.

Areas covered: This review provides an overview of the economic literature on the use of ICIs to treat lung cancer. Numerous papers have been published over the last few years. Cancers analyzed were non-squamous non-small-cell lung cancer (NSCLC), squamous NSCLC, locally advanced NSCLC, or small-cell lung cancer.

Expert commentary: For the majority of patients, ICIs are cost-effective for lung cancer management. However, these results are influenced by the threshold chosen by each of the different countries. Patient selection, treatment duration, and factors predictive of efficacy are mandatory to decrease costs.

摘要

简介：肺癌管理总成本正在急剧增加。免疫检查点抑制剂 (ICI) 的广泛使用在很大程度上解释了这种增长，并对医疗保健系统产生了财务影响。经济评估已适应这一新挑战。

涵盖的领域：本综述概述了关于使用 ICI 治疗肺癌的经济文献。过去几年发表了许多论文。分析的癌症是非鳞状非小细胞肺癌 (NSCLC)、鳞状 NSCLC、局部晚期 NSCLC 或小细胞肺癌。

专家评论：对于大多数患者而言，ICI 对肺癌管理具有成本效益。然而，这些结果受到每个不同国家选择的阈值的影响。患者选择、治疗持续时间和疗效预测因素是降低成本的必要条件。